Given that high-grade CRC tumors are generally characterized by increased cellular proliferation and often exhibit a more aggressive phenotype, the observed upregulation of SIGLEC9 protein expression—an established immune checkpoint that suppresses immune responses—suggests that SIGLEC9 could be involved in immune surveillance evasion more in high-grade tumors than in low-grade CRC tumors. Here, SIGLEC9 is linked to colorectal carcinoma.